Where can I buy Amivantamab more reliably?

Introduction: Amivantamab is a fully human bispecific antibody targeting EGFR and MET with immune cell-directed activity. It has been approved in the United States, Europe and other markets around the world as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertion mutations detected by an FDA-approved test and whose disease has progressed during or after platinum-based chemotherapy.

Where to buy Amivantamab more reliably

When purchasing , you should choose formal and reliable channels and use it under the guidance of professional doctors. You can refer to the following .

1. Hong Kong, China: Patients can go to hospitals in Hong Kong, China, and purchase evantumumab in the hospital’s pharmacy. A medical prescription is usually required for purchase. Patients can also purchase evantumumab in local pharmacies in Hong Kong, China, and a medical prescription is required before purchase.

2. Overseas purchase: Patients can also purchase evantumumab through overseas channels, such as going abroad to purchase the drug on their own, or entrusting relatives and friends to help purchase evantumumab. They can buy the original version of evantumumab.

3. Participation in clinical trials: Patients can participate in domestic evantumumab clinical trials. If they meet the clinical recruitment conditions, they can also obtain evantumumab after enrollment.

4. Medical service institutions: Patients can also purchase evantumumab through domestic medical service institutions. They can purchase the original research version or the version exported to other countries.

Evantumumab needs to be used under the guidance of a doctor, and the usage and dosage should be strictly in accordance with the doctor's instructions.

Dosage of evantumumab

The recommended dose of evantumumab is 1050 mg (body weight below 80 kg) and 1400 mg (body weight equal to or greater than 80 kg). It is administered once a week for four weeks. The initial dose is divided into two infusions, the first week, the first day and the second day, and then every two weeks. Throughout the course of evantumumab treatment, patients are advised to remain on treatment until disease progression is observed while on treatment, or until unacceptable toxicity develops.

Pharmacokinetics of evantumumab

Evantumumab is administered intravenously once a week for 4 weeks, then every 2 weeks until disease resolution. The pharmacokinetic profile of evantumumab showed significant differences in drug exposure between the fifth and first doses, and multiple dosing regimens may produce drug accumulation.

After 2 months of dosing every 2 weeks, at the ninth infusion, the concentration of the drug in the body reached a stable equilibrium state, and the dose was 1050mg at this time. The average initial area under the curve is higher at this equilibrium point compared to the initial dose. No clinically significant effects of evantumumab exposure were observed related to sex, race, age, mild hepatic impairment, or creatinine clearance.